MedTrace Logo

Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa

NCT04604899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-07-16

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to assess the safety of repeat injection of human retinal progenitor cells (jCell) in adult subjects with RP that have previously been treated with jCell.

Conditions

Interventions

BIOLOGICAL

human retinal progenitor cells

single intravitreal injection of 6.0 million human retinal progenitor cells (hRPC)

Sponsors & Collaborators

  • California Institute for Regenerative Medicine (CIRM)

    collaborator OTHER

  • jCyte, Inc

    lead INDUSTRY

Principal Investigators

  • Mitul Mehta, MD · University of California, Irvine/Gavin Herbert Eye Institute

  • David Liao, MD · Retina-Vitreous Associates Medical Group, Los Angeles CA

  • Anthony Jospeh, MD · Ophthalmic Consultants of Boston

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-03-22
Completion
2022-03-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04604899 on ClinicalTrials.gov